Century Therapeutics, Inc. (IPSC)

2,5600 -0,1200 (-4,48%) Börsenschluss: 04:00PM EDT

Century Therapeutics, Inc.

25 North 38th Street
11th Floor
Philadelphia, PA 19104
United States
267 817 5790
https://www.centurytx.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 152

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Brent Pfeiffenberger M.B.A., Pharm.D.	CEO & Director	274,06k	N/A	N/A
Dr. Adrienne Farid Ph.D.	COO & Head of Early Development	670,29k	N/A	1962
Dr. Gregory Russotti Ph.D.	Chief Technology & Manufacturing Officer	852,56k	N/A	1967
Mr. Douglas Carr CPA	Interim Principal Financial Officer, Senior VP of Finance & Operations and Secretary	N/A	N/A	N/A
Mr. Kenneth J. Dow J.D.	Senior VP of General Counsel	N/A	N/A	N/A
Dr. Shane Williams Ph.D.	Chief People Officer	N/A	N/A	N/A
Dr. Hyam I. Levitsky M.D.	President of Research & Development	502,12k	N/A	1958
Michael Naso Ph.D.	Senior VP of Cell Engineering	N/A	N/A	N/A
Dr. Nick Trede M.D., Ph.D.	Senior VP & Head of Clinical Development	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Corporate Governance

Century Therapeutics, Inc.s ISS Governance QualityScore, Stand 1. Juni 2024, lautet 7. Die grundlegenden Scores sind Audit: 8, Vorstand: 5, Shareholderrechte: 8, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.